Pigmented Villonodular Synovitis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Pigmented Villonodular Synovitis – Pipeline Review, H2 2016’, provides an overview of the Pigmented Villonodular Synovitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pigmented Villonodular Synovitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pigmented Villonodular Synovitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Pigmented Villonodular Synovitis

The report reviews pipeline therapeutics for Pigmented Villonodular Synovitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Pigmented Villonodular Synovitis therapeutics and enlists all their major and minor projects

The report assesses Pigmented Villonodular Synovitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Pigmented Villonodular Synovitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pigmented Villonodular Synovitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pigmented Villonodular Synovitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Daiichi Sankyo Company Ltd

F. Hoffmann-La Roche Ltd

Five Prime Therapeutics Inc

Novartis AG

Plexxikon Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Pigmented Villonodular Synovitis Overview 6

Therapeutics Development 7

Pipeline Products for Pigmented Villonodular Synovitis - Overview 7

Pigmented Villonodular Synovitis - Therapeutics under Development by Companies 8

Pigmented Villonodular Synovitis - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Pigmented Villonodular Synovitis - Products under Development by Companies 11

Pigmented Villonodular Synovitis - Companies Involved in Therapeutics Development 12

Daiichi Sankyo Company Ltd 12

F. Hoffmann-La Roche Ltd 13

Five Prime Therapeutics Inc 14

Novartis AG 15

Plexxikon Inc 16

Pigmented Villonodular Synovitis - Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Drug Profiles 26

cabiralizumab - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

emactuzumab - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

MCS-110 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

nilotinib - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

pexidartinib - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

PLX-73086 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Pigmented Villonodular Synovitis - Product Development Milestones 41

Featured News & Press Releases 41

May 12, 2016: Five Prime Therapeutics Advances FPA008 Into Phase 2 Dose Expansion in Patients with Pigmented Villonodular Synovitis 41

Jan 13, 2016: Five Prime Therapeutics Receives FDA Orphan Drug Designation for FPA008 in Pigmented Villonodular Synovitis 41

Jul 13, 2015: Five Prime Therapeutics Initiates Patient Dosing in Phase 1/2 Clinical Trial Evaluating FPA008 in Pigmented Villonodular Synovitis 42

Jun 01, 2014: Roche to present phase I data on investigational cancer immunotherapy anti-CSF-1R (RG7155) antibody in patients with Pigmented Villonodular Synovitis 42

May 14, 2014: Plexxikon Announces PLX3397 Data Presentations at ASCO 2014 Annual Meeting 44

May 14, 2014: Plexxikon Announces Promising Preliminary PLX3397 Phase 1 Extension Data in Patients with Pigmented Villonodular Synovitis 44

Appendix 46

Methodology 46

Coverage 46

Secondary Research 46

Primary Research 46

Expert Panel Validation 46

Contact Us 46

Disclaimer 47

List of Tables

List of Tables

Number of Products under Development for Pigmented Villonodular Synovitis, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Pigmented Villonodular Synovitis – Pipeline by Daiichi Sankyo Company Ltd, H2 2016 12

Pigmented Villonodular Synovitis – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 13

Pigmented Villonodular Synovitis – Pipeline by Five Prime Therapeutics Inc, H2 2016 14

Pigmented Villonodular Synovitis – Pipeline by Novartis AG, H2 2016 15

Pigmented Villonodular Synovitis – Pipeline by Plexxikon Inc, H2 2016 16

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Stage and Target, H2 2016 19

Number of Products by Stage and Mechanism of Action, H2 2016 21

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 25

List of Figures

List of Figures

Number of Products under Development for Pigmented Villonodular Synovitis, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 10

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Targets, H2 2016 18

Number of Products by Stage and Targets, H2 2016 18

Number of Products by Mechanism of Actions, H2 2016 20

Number of Products by Stage and Mechanism of Actions, H2 2016 20

Number of Products by Routes of Administration, H2 2016 22

Number of Products by Stage and Routes of Administration, H2 2016 22

Number of Products by Molecule Types, H2 2016 24

Number of Products by Stage and Molecule Types, H2 2016 24

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports